It's been a rocky few months for Novo Nordisk.Prescription data from IQVIA suggests Novo's obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stock has fallen more than 20% over the last year, and people feared things would get even worse when the company released fourth-quarter earnings and its 2025 outlook on Wednesday.Instead, Novo beat fourth-quarter expectations ...

Shares of Novo Nordisk (NVO 4.33%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 (^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite (^IXIC -0.05%) lost 0.1% on the day.The numbersThe pharmaceutical giant and maker of Ozempic and Wegovy reported better-than-expected numbers Wednesday morning. The drugmaker delivered 25% year-over-year (YOY) revenue growth, with 2024 sales coming in at $40.5 ...

It is always easy to say "I told you so" because in hindsight we almost always know better. This is so common it even has a name - the hindsight bias, which describes how people tend to edit their memories to look better orMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (fr ...

I love consumer instinct.Thank you, Peter Lynch, for teaching us about using our instincts as consumers along with megatrends and technical analysis. Last night we went to a dinner party and the conversation turned to Bowling Green, Nebraska, the Ozempic capital of the U.S. On December 2, 2024, I wrote a Daily called, Novo-Nordisk, A Love Story. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty if you're human: I wrote, “According to an article ...

Novo Nordisk A/S (NVO) reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 83 cents. The company had reported earnings of 71 cents per ADR in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues of $12.3 billion increased 30% in the Danish kroner (DKK) and at the constant exchange rate (CER) in the reported quarter. Total revenues surpassed the Zacks Consensus Estimate of $11.3 billio ...

Hi there, welcome to my profile. My name is Eugenio Catone, I live in Italy and I am 26 years old. In 2023 I graduated in Business Administration and I am completing my studies. My interest in financial markets started about 5 years ago when I accidentally came across a video about trading. That was the spark that introduced me to a new world, but over time I realized that it was not my path: too many charts, lines, and not very concrete concepts for a pragmatic person like me. I needed something different ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Pharmaceutical concern Novo Nordisk A/S (NYSE:NVO) is up 4.9% at $86.63 at last glance. The company posted strong fourth-quarter results and better-than-expected full-year revenue for 2024, as weight-loss drugs Wegovy and Ozempic reeled in billions, though sales are expected to slow this year amid supply shortages. CEO Lars Fruergaard Jorgensen also spoke to journalists after the report, saying the Danish drugmaker is well-positioned to deal with potential tariffs by the U.S. On the charts, today's pop has ...

The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn moreEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing g ...

Figure 10 Gold in soil geochemistry and main prospects of the Tabba Tabba Shear Corridor Figure 11 Balla Balla Project geology showing the Sholl Shear Zone and complex folded stratigraphy Figure 12 East Pilbara tenement location map, showing Miralga District and key prospects. Figure 13 Belltopper Gold Project location map with regional gold occurrences and major structures (18) Figure 14 Location of Priority Tenements adjacent to Azure Minerals’ (ASX: AZS)Andover Lithium – Nickel Project ...